New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
10:12 EDTAVGO, RDY, ENOC, LLY, YUM, BGS, VRA, TSO, RFMD, MCHP, MTB, HBC, GLF, FRME, DRC, BBEP, CRLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Avago (AVGO) upgraded to Buy from Neutral at Goldman... BreitBurn Energy (BBEP) upgraded to Neutral from Underperform at Credit Suisse... Charles River Labs (CRL) upgraded to Outperform from Market Perform at Wells Fargo... Dresser-Rand (DRC) upgraded to Positive from Neutral at Susquehanna... First Merchants (FRME) upgraded to Outperform from Market Perform at Keefe Bruyette... GulfMark Offshore (GLF) upgraded to Outperform from Market Perform at Wells Fargo... HSBC (HBC) upgraded to Buy from Hold at Deutsche Bank... M&T Bank (MTB) upgraded to Outperform from Market Perform at Keefe Bruyette... Microchip (MCHP) upgraded to Neutral from Sell at Goldman... RF Micro Devices (RFMD) upgraded to Overweight from Equal Weight at Barclays... Tesoro (TSO) upgraded to Outperform from Neutral at Credit Suisse... Vera Bradley (VRA) upgraded to Buy from Hold at Jefferies... B&G Foods (BGS) upgraded to Outperform from Sector Perform at RBC Capital... Yum! Brands (YUM) upgraded to Buy from Neutral at Goldman... Charles River Labs (CRL) upgraded to Overweight from Neutral at JPMorgan... Eli Lilly (LLY) upgraded to Neutral from Underperform at Cowen... EnerNOC (ENOC) upgraded to Outperform from Market Perform at Raymond James... Dr. Reddy's Labs (RDY) upgraded to Outperform from Neutral at Credit Suisse.
News For AVGO;BBEP;DRC;FRME;GLF;HBC;MTB;MCHP;RFMD;TSO;VRA;BGS;YUM;LLY;ENOC;RDY;CRL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 21, 2014
14:04 EDTRFMD, AVGOEarnings Preview: Analysts divided on Broadcom ahead of Q3 report
Subscribe for More Information
11:30 EDTBBEPOptions with decreasing implied volatility
Subscribe for More Information
08:32 EDTLLYFDA accepted NDA for empagliflozin plus
Subscribe for More Information
07:15 EDTLLYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
18:51 EDTRFMD, AVGOOn The Fly: After Hours Movers
Subscribe for More Information
18:22 EDTAVGO, RFMDSkyworks Solutions, Cirrus Logic, others higher after Apple reports Q4 results
The following stocks are moving higher in the after hours following Apple's Q4 results: ARM Holdings (ARMH) is up 1.1%, Skyworks Solutions (SWKS) is higher by 2.2% ,NXP Semiconductors (NXPI), up 2.28%,Cirrus Logic (CRUS) is up 2%, RF Micro Devices (RFMD) gains 1.53% and Avago Technologies (AVGO) is up 1.17%.
18:04 EDTGLFGulfMark Offshore expects FY15 revenue $480M-$530M, consensus $575.48M
18:03 EDTGLFGulfMark lowers FY14 revenue guidance to $490M-$495M, consensus $519.02M
Subscribe for More Information
18:02 EDTGLFGulfMark Offshore expects Q4 revenue $110M-$115M, consensus $136.52M
18:01 EDTGLFGulfMark Offshore reports Q3 ex-items EPS 75c, consensus 82c
Subscribe for More Information
14:29 EDTMCHPEarnings Preview: Texas Instruments down 9% over last three months
Semiconductor maker Texas Instruments (TXN) is expected to report third quarter earnings after the close on Monday, October 20, with a conference call scheduled for 5:30 pm ET. EXPECTATIONS: Analysts are looking for earnings per share of 71c on revenue of $3.46B. The consensus range is 66c-74c for EPS on revenue of $3.44B-$3.5B, according to First Call. Along with its last earnings report, Texas Instruments guided to Q3 EPS of 66c-76c on revenue of $3.31B-$3.59B. LAST QUARTER: On July 21, Texas Instruments reported second quarter EPS of 62c, which was higher than analysts' consensus of 59c. The company's revenue of $3.29B exceeded analysts' expectation of $3.27B. Texas Instruments noted that the restructuring changes which occurred in Q2 are positioned to be nil in Q3 and noted that it anticipated utilization in Q3 to remain consistent with Q2 levels. NEWS: On September 18, Texas Instruments increased its quarterly dividend by 13% to 34c. WHAT'S NOTABLE: After the close on October 9, Microchip (MCHP), which develops microcontroller and analog semiconductors, said that it had experienced a number of negative trends during the quarter, including a weaker than usual September, weakness in China, and significant inventory builds at its distributor customers. Microchip President and CEO Steve Sanghi claimed his company often sees the turn of the semiconductor industry ahead of others, noting that it reports sales from distribution on a sell-through basis and that it does business with over 80,000 customers. Sanghi stated, "We believe that another industry correction has begun and that this correction will be seen more broadly across the industry in the near future." STREET RESEARCH: Analysts were fairly quiet on Texas Instruments during the quarter. The day after the company issued its Q2 earnings report, Sterne Agee believed that Texas Instruments' commentary on 4G telecom, auto and industrial strength should be positive for Spansion (CODE). RBC Capital noted on the same day that Texas Instruments had "strong" Q2 results, particularly in its execution, while its operating margin leverage was "impressive. The firm maintained a $57 price target and Outperform rating on the stock. On July 24, Tigress Financial upgraded Texas Instruments to Neutral from Underperform. PRICE ACTION: Over the last three months, Texas Instruments' shares are down about 9%. Since October 10, the day after Microchip's warning on the industry correction it believes has begun, Texas Instruments shares are down over 3%. In afternoon trading before tonight's report, Texas Instruments was up 1.7% to $44.41.
13:10 EDTVRASteve Madden tumbles after providing preliminary Q3 results, FY14 outlook
Shares of shoe and accessory company Steve Madden (SHOO) are tumbling after the company announced preliminary third quarter results that were below analysts' consensus along with a reduction to its fiscal year 2014 outlook. WHAT'S NEW: Steve Madden announced that it is anticipating Q3 earnings per share to be approximately 61c-62c and net sales of $392M, below analysts' consensus estimates of 67c and $415.72M, respectively. The company noted that retail comparable store sales for the quarter are anticipated to be down 7.4%. Steve Madden also reduced its FY14 EPS outlook to $1.81-$1.86 from $2.00-$2.10, well below analysts' $2.02 consensus. The company lowered its net sales projection for the year, and now sees net sales up 1%-2% over fiscal year 2013 versus its previous net sales guidance for up 2%-4% over FY13. The new guidance factors in the recent acquisition of Dolce Vita and current expectations for remainder of the year. On August 14, Steve madden acquired Dolce Vita for $60.3M in cash and previously said the deal would be accretive to earnings in FY14 by 2c-3c and be "modestly accretive" in FY15. WHAT'S NOTABLE: Steve Madden's Chief Executive Officer Edward Rosenfeld said that the company's Q3 earnings were "disappointing" and were the result of weaker than expected retail segment performance. He believes that retail trends in the footwear space will continue to be difficult through the fourth quarter due to a lack of noteworthy fashion trends in the industry. The CEO said that the company's full-year guidance results from this pattern, along with a lowered reorder outlook in its wholesale segment. Rosenfeld is still confident, however, in the company's business model and believes that its acquisitions of Dolce Vita and its Mexican licensee will fuel the business forward over the long term. OTHERS TO WATCH: Competitors of Steve Madden include Michael Kors (KORS), Coach (COH), Kate Spade (KATE), and Vera Bradley. PRICE ACTION: During afternoon trading, shares of Steve Madden fell $2.62 or 8.2%, to $29.32. Over the last twelve months, the stock has fallen over 15%.
08:33 EDTBBEPBreitBurn Energy provides update on QR Energy acquisition
Breitburn Energy Partners LP (BBEP) announced that the Registration Statement on Form S-4 concerning Breitburn’s acquisition of QR Energy, LP (QRE) was declared effective by the SEC on October 17, 2014. QR Energy will hold a special meeting of its unitholders on November 18, 2014, at 2:00 p.m., Central Time, at the Four Seasons Hotel, 1300 Lamar Street, Houston, Texas. QR Energy unitholders of record at the close of business on October 13, 2014, will be entitled to receive notice of the special meeting and to vote at the special meeting. The transaction, which was announced on July 24, 2014, was unanimously approved by the boards of directors of Breitburn and QR Energy. In addition, certain QR Energy unitholders owning approximately 37% of the votes of the outstanding QR Energy units have agreed to vote in favor of the transaction. Completion of the transaction is subject to the approval of QR Energy unitholders and customary closing conditions. The transaction is expected to close in late November.
October 17, 2014
10:51 EDTLLYOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
08:11 EDTMTBM&T Bank reports Q3 non-GAAP EPS $1.94, consensus $1.98
Subscribe for More Information
October 16, 2014
15:26 EDTMTBNotable companies reporting before tomorrow's open
Subscribe for More Information
14:36 EDTLLYLilly to close Guayama facility, will take 16c charge in Q4
Eli Lilly announced plans to conclude production and pursue a sale of one of its three manufacturing plants in Puerto Rico. The manufacturing site, located in Guayama, Puerto Rico, will remain in operation until the end of 2015. All of the approximately 100 full-time non-contracted employees currently working in Guayama will be offered employment at Lilly's Carolina, Puerto Rico, location. As a result of this action, the company expects to record a charge of approximately $170M or approximately 16c per share, after tax, in Q414. While Lilly will initiate efforts to sell the Guayama site, the company will continue to invest in two manufacturing plants at Carolina. In November 2013, Lilly announced a $200M investment to increase capacity in its Carolina-based insulin active ingredient manufacturing plant. In July, Lilly announced an additional $40M in investments to increase capabilities at its Carolina-based drug product site as part of a rebalancing of Lilly's oral solid dosage network.
14:18 EDTAVGOAvago upgraded to Buy with $87 target at Brean Capital
Subscribe for More Information
14:16 EDTAVGOAvago upgraded to Buy from Hold at Brean Capital
Subscribe for More Information
07:19 EDTBGSB&G Foods poised to rebound in 2H14, says RBC Capital
RBC Capital expects B&G's Q3 results to show reduced promotion spending and improving margins. The firm is also upbeat about the company's new CEO and keeps a $36 price target and Outperform rating on the shares.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use